Patients that fully recovered from depression

10,705

Clinicians using Flow

20 000

Eir patients within NHS

34,000

Flow offers a much-needed treatment option—at-home tDCS—that can be used alone or alongside existing care to fill a key gap in depression treatment.

Flow is based on Transcranial direct current stimulation as a non-invasive, painless and safe brain stimulation technology.

How to partner with us
Easy

At-home treatment with built-in onboarding.
Effortlessly review patient’s adherence and progress.

Adherence rate
78%
Efficient

Remarkable results already after 3 weeks.
Standalone or augmented to current treatment plans.

Remission rate*
57.5%
* Remission defined as a score of ≤12 on MADRS
Safe

Clinically proven to treat and prevent depression without the side-effects. Used by the NHS. Approved by EMA.

Significant side effects
0

Meet our products

Flow and Flow Connect

At Flow Neuroscience, we are committed to broadening access to clinically effective mental health treatments, empowering clinicians to offer innovative care options for their patients:
Eir and Flow Connect.

Flow
Advanced tDCS neurostimulation device designed for depression treatment with precise, safe electrical stimulation monitored by a comprehensive mobile application that guides treatment sessions.
Learn more
Flow Connect
Professional monitoring platform for healthcare providers to track patient progress and adjust treatment protocols with Real-time monitoring, Patient dashboard and Clinical insights.
Learn more

Proven reduction in

symptoms by week 6–10.

Patients track their progress using the MADRS-s within the Flow app.

Review outcome data

Average symptom reduction (points by week 10)

6.4

Adherence in early treatment weeks

High

Engagement with mobile guidance

Sustained